Background: Von Hippel-Lindau disease (VHL) is a rare autosomal dominant inherited disorder characterized by highly vascularized tumors in various organs. The abundant presence of endothelial cells in VHL tumors strongly suggest a role of the VHL tumor suppressor gene in the regulation of angiogenesis. Recently, in vitro studies have shown that the VHL tumor suppressor gene regulates the expression of vascular endothelial growth factor (VEGF). We investigated whether VHL patiens have increased levels of VEGF in their body fluids.
Introduction
Characteristic for von Hippel-Lindau (VHL) disease, a rare autosomal dominant disorder, is the development of extremely vascularized tumors: hemangioblastomas of the central nervous system, angiomas of the retina, renal cell carcinomas and pheochromocytomas. Other manifestations of the disease are the development of cysts in target organs of the disease: liver, pancreas, kidneys, adrenal gland, epididymis and central nervous system [1, 2] . The well-vascularized phenotype of VHL tumors suggests that inactivation of the VHL gene induces upregulation of an angiogenic factor or downregulation of an inhibitor of angiogenesis. A role for the tumor suppressor gene p53 in the regulation of angiogenesis has been described. Thrombospondin, an inhibitor of angiogenesis, and vascular endothelial growth factor (VEGF), an endothelial cell specific mitogen, are under the control ofp53 [3, 4] Little is known about the function of the VHL gene product. Production of the VHL protein is not restricted to the target organs and can be detected in virtually all organs [5] . Recently, it was recognized that the VHL gene product is a negative regulator of the transcription elongation factor elongin [6] [7] [8] . The first evidence that VEGF might be overexpressed in VHL disease came from an immunohistochemical study of VHL-associated hemangioblastomas. VEGF and its receptors were found to be upregulated in these highly vascularized brain lesions [9] . In vitro studies showed that human renal cell carcinoma cells which lacked the endogenous wild-type VHL gene expressed high levels of vascular endothelial growth factor (VEGF) mRNA and VEGF protein. Introduction of the wild-type VHL cDNA resulted in a downregulation of VEGF production [10] [11] [12] .
VEGF is considered to be one of the most important angiogenic factors [13] [14] [15] . VEGF gene expression is induced by hypoxia, steroid hormones, protein kinase C agonists, reactive oxygen intermediates and iron deficiency [16] [17] [18] [19] [20] . Three high affinity tyrosine kinase recep- Patient   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15   Mutation   V241D  V241D  V241D  V241D  V241D  Deletion exon 1 & 2  V241D  V241D  V241D  R238Q  V241D  V241D  V241D  Unknown  R238Q   Age   57  22  31  31  28  33  28  28  61  40  38  50  34  51  29 Sex tors for VEGF have been identified. These receptors appear to be expressed specifically by endothelial cells [21] [22] [23] . Furthermore VEGF, also known as vascular permeability factor (VPF), is a potent inducer of microvascular permeability. On molar basis, VPF is some 50,000 times more potent than histamine at increasing microvascular permeability [24] . Elevated expression of VEGF has been demonstrated in tumors of the central nervous system, gastrointestinal tract, kidney and breast [25] [26] [27] .
Because the majority of VHL patients will get manifestations of the disease before the age of 65, insight in the regulation of angiogenesis by the VHL tumor suppressor gene may facilitate the development of a treatment to delay or prevent VHL-related tumors. To investigate whether angiogenic factors are overexpressed in patients with VHL disease, body fluids of these patients were tested for the presence of four different endothelial mitogens: VEGF, basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), and endothelin-1 (ET-1).
In this study we observed a strong positive correlation between age and VEGF levels in aqueous fluid from the anterior chamber of the eye of both, the VHL patients and controls. At comparable age, VEGF levels in ocular fluid of VHL patients were higher than in the control group (P < 0.001). In addition, VEGF concentrations in renal cyst fluids were 10 and 16 fold higher than serum levels. The average VEGF concentration was higher in serum and lower in urine of VHL patients than in matched controls, although this did not reach significance. These findings support the in vitro observations that VEGF is regulated by the VHL gene and suggest a role for VEGF in the pathogenesis of VHL tumors and cyst development.
Patients and methods

Patients
Two groups of VHL patients were analyzed in the present study. A Dutch population consisting of fifteen patients from five different families, seven men and eight women, was entered in a protocol to collect serum, urine and ocular fluid samples The study protocol was approved by the Ethics Committee of the University Hospital Utrecht and all patients gave informed consent. The clinical manifestations of VHL disease, age and sex of the Dutch patients are listed in Table 1 . In addition, with the help of the American VHL family alliance, twenty American VHL patients volunteered to provide urine samples for our study. Control samples of blood and urine were collected from unaffected volunteers matched for age and sex. Control samples of ocular fluid were taken from patients undergoing cataract surgery.
Samples
Collection of ocular fluid
The corneas of VHL patients and unaffected subjects undergoing cataract surgery were anesthesized with 0.4% oxybuprocain and 1% tetracain eyedrops three times with an interval of 10 minutes. With the aid of a surgical microscope a pre-incision with a depth of 3 mm was made in the peripheral cornea next to the limbus. Fifty to 200 ul aqueous humor was obtained from the anterior chamber by introducing a 27 G x 1.2* needle on a tuberculine syringe (Plastipak R, Becton Dickinson). The ocular fluid samples were collected in sterile tubes, placed on ice immediately and rapidly frozen at -70 °C until further use. If control subjects had an abnormal retina at fundoscopy after lens extraction the aqueous humor was excluded from the study.
Collection of cyst fluid, serum, and urine
Renal cyst fluid was collected by needle aspiration from two different cysts in two kidneys. Cyst fluid was cleared by centrifugation and stored at -70 C C until further use. Serum samples were aliquoted and stored at -70 °C until use for analysis. In three patients undergoing surgery, blood from the vena renales was taken simultaneously with blood from peripheral veins. First urine of the day was collected, cleared by centrifugation at 3000 rpm for 10 min, aliquoted and stored at -70 C C. ELISA procedures VEGF protein concentrations in serum, urine, cyst and ocular fluid were measured in duplicate using a VEGF-ELISA (R&D Systems) Ocular fluid and cyst fluid samples were diluted (one into four and one into 10, respectively) in dilution fluid provided by the manufacturer. bFGF and IL-8 concentrations in serum and urine were determined in duplicate using a bFGF-ELISA (R&D Systems) and a IL-8 ELISA (Medgenix diagnostics). ET-1 was measured in serum using a RIA (Nichols Institute) as described elsewhere [26] , All ELISA's were performed following the instructions of the manufacturer.
Immunohistochemlstrv
Between 1982 and 1996, seven renal cell carcinomas and three hemangioblastomas from the Dutch VHL patients were removed by surgery at the University Hospital Utrecht. All tumor samples were routinely fixed and paraffin embedded. Sections of paraffin embedded tumors were de-paraffinized with xylene and washed in ethanol. age (years) Figure 1 . Correlation of VEGF concentrations, in aqueous humor of the anterior chamber of the eye, with age in patients with VHL disease and control individuals.
Statistical methods VEGF, bFGF, IL-8 and ET-1 concentrations in ocular fluid, serum and urine were expressed as the mean ± standard error of the mean (SEM). Statistically significant differences between VHL patients and unaffected controls were determined using a two-way Mann-Withney U-test. VEGF concentration in ocular fluid and age correlations were determined with linear regression analysis.
Results
VEGF concentration in ocular fluid of VHL patients
VEGF concentrations in aqueous fluid of the anterior chamber of the eyes of 10 VHL patients and 15 control subjects were measured. The retinas of the eyes of VHL patients from which the ocular fluid was taken showed either no or very small angiomas ( Table 1) . None of the control subjects included in this study had retinal abnormalities at fundoscopy. The detection level of the VEGF-ELISA was 5 pg/ml. VEGF was detectable in eight out of 10 ocular fluid samples of VHL patients ( Table 2 ). The mean concentration of VEGF in ocular fluid of VHL patients was 51 ± 10 pg/ml (range 22-111). In the control group VEGF was detectable in nine out of 15 ocular fluid samples with a mean of 48 ± 9 pg/ml (range 28-145). The control group (mean age of 69 years, range 47-90) was older than the VHL group (mean age of 38 years, range 29-61). In both groups a strong, linear correlation was observed between age and VEGF concentration (r = 0.90 and r -0.72, for VHL patients and the control group, respectively) ( Figure 1 ). Linear regression analysis showed that the VEGF concentrations in ocular fluid of VHL patients at comparable age are 88 pg/ml higher than the control group (P < 0.001).
VEGF concentration in cyst fluid, serum, and urine of VHL patients
Cyst fluid. The concentration of VEGF in fluid of two renal cysts derived from different kidneys of VHL patient 14 was measured. In both cysts a high level of VEGF was observed: 12.2 and 19.9 ng/ml. The VEGF serum level of this patient was 1.2 ng/ml.
Serum levels. VEGF levels were measured in serum of fifteen Dutch VHL patients and matched unaffected controls. The VEGF concentrations of all patients are presented in Table 2 . The mean concentration of VEGF in serum of VHL patients (319 ± 84 pg/ml) was higher than in the control group (238 ± 68 pg/ml) but did not reach significance. No correlation between VEGF levels and the presence of manifestations of VHL disease was found. More specifically, patients with renal cell cancer either had a high (patient 14) or low (patient 10) concentration of VEGF. Three patients (patients 5, 6 and 10) had localized renal cell cancer and underwent nefron sparing surgery. At the time of surgery blood samples were taken from the vena renales of the affected kidney. VEGF levels in serum obtained from the renal veins were identical to the peripheral blood serum levels.
Urine levels. VEGF levels were measured in urine of thirteen VHL patients and matched controls ( Table 2) . Urinary VEGF levels of the control group were not significantly different from urinary VEGF levels of VHL patients (183 ± 25 pg/ml and 128 ± 36 pg/ml, respectively, P = NS).
bFGF concentration in serum and urine of patients with VHL disease
bFGF levels were measured in serum of Dutch VHL patients and matched controls. Results are presented in Table 2 . Concentrations of bFGF in serum of VHL patients (mean 4.7 ± 2.1 pg/ml) and in the control group (mean 4.3 ± 1.5 pg/ml) were similar. bFGF levels were measured in urine of Dutch and American VHL patients (n -31). There was no difference between urinary bFGF levels of VHL patients (2.2 ± 0.3 pg/ml) and matched controls (2.3 ± 1.9 pg/ml). Urinary bFGF levels did not correlate with the presence of manifestations of VHL disease.
IL-8 and ET-1 concentration in serum and urine of patients with VHL disease
IL-8 concentrations were measured in serum samples of the VHL patients and matched controls. IL-8 levels were comparable in serum of VHL patients and of control subjects (23.1 ± 4.8 pg/ml and 32.2 ± 4.6 pg/ml, respectively). IL-8 concentrations in urine samples of the Dutch and American VHL patients (n = 31) were 29.3 ± 6 pg/ml and in the control group (n -41) 24.4 ± 3 pg/ml. Results of the Dutch VHL patients are shown in Table 2 . ET-1 was measured in a limited number of serum samples of Dutch VHL patients (n = 6). The mean concentration of ET-1 was 2.5 ± 0.6 (pmol/1). Values of ET-1 above 6 pmol/1 are considered to be elevated [28] .
Expression of VEGF and bFGF in VHL-related tumors
Seven renal cell carcinomas (from patients 4, 5, 6, 8, 10, and a bilateral renal cell cancer from patient 13) and three hemangioblastomas (patients 5, 6, and 13) were tested for their immuno-reactivity with anti-VEGF and anti-bFGF antibodies. Abundant expression of VEGF was observed in all renal cell carcinomas and in all hemangioblastomas. bFGF expression was absent in three renal cell cancers. Two renal cell cancers showed a low level of expression (less than 5% of tumor cells were positive) and one renal cell cancer had a weak expression (less than 20% of tumor cells were positive). In two hemangioblastomas a moderate bFGF expression was observed and in one hemangioblastoma a mild immunoreactivity for bFGF was seen. Immuno-staining with antibodies against endothelial cell markers CD34 and F8-RA demonstrated the abundant vascularity of VHLrelated renal cell carcinomas and hemangioblastomas ( Figure 2 ).
Discussion
The clinical manifestations of VHL disease suggest that the VHL tumor suppressor gene is involved in the regulation of angiogenesis. Transfection experiments and immunohistochemistry have shown that VEGF is overexpressed when the VHL gene is mutated [9] [10] [11] [12] . Retinal angiomatosis, frequently bilateral, occurs in more than 70% of VHL patients before the age of sixty years [29] . The major complication is retinal detachment, sometimes complicated by vitreous hemorrhage, with danger of blindness [1] . In the present study VEGF was detectable in 80% of the VHL patients and 60% of the control subjects. A strong positive correlation for both groups existed between age and VEGF concentration. However, there was a significant leftwards shift of the curve for VHL patients. Interestingly, the presence of retinal angiomas did not correlate with increased VEGF concentrations. However, the development of angiomas is most likely a multistep process which requires multiple changes at the cellular level of the retina. At the moment, it is unclear in what phase of the multi-step process the VHL-tumor cells acquire the capacity for overproduction of VEGF. Clearly, VEGF alone is not sufficient for the development of angiomas, because the elderly patients who had high levels of VEGF did not develop angiomas. It may be speculated that VEGF production is either an early or a late event in the cascade caused by losing the second VHL allele. Other factors as yet undefined may also be involved in the angiogenic switch.
•c AHnnriant AvnrACcmn r\f V P H F vivac i*»Kc^rv^H in r^nal i"**»ll carnnAma ^A\ Figure 2 . Expression of VEGF, bFGF, CD34and F8-RA in VHL-related tumors. Abundant expression of VEGF was observed in renal cell carcinoma (A) and hemangioblastoma (B). Low expression of bFGF was seen in renal cell carcinoma (C) and moderate expression in hemangioblastoma (D). Immunoreactivity of CD34 in renal cell carcinoma (E) and F8-RA in hemangioblastoma (F) showed that these tumors are extremely vascularized A role for VEGF in the development of retinal angio-retinal fluid), VEGF concentrations of the posterior-A role for VEGF in the development of retinal angioma is supported by the observation that VEGF concentrations are elevated in the vitreous and anterior chamber fluid of patients with active retinal and anterior-segment neovascularization associated with several ocular diseases [30, 31] . However, it could be argued that VEGF levels in the anterior chamber do not reflect VEGF concentrations in the retina. In simultaneously collected samples of fluid from the anterior segment (aqueous humor) and the posterior segment (either vitreous humor or subretinal fluid), VEGF concentrations of the posteriorsegment exceeded the aqueous concentration [30] . Based on these observations it is likely that retinal concentrations of VEGF are even higher than the VEGF levels measured in ocular fluid of the anterior chamber. Although VEGF is associated with pathological ocular angiogenesis, little is known about the physiological concentrations of VEGF in the eye. In contrast to our findings, a recent study failed to detect VEGF, using ELISA's with comparable sensitivity, in the majority of the patients without signs of ocular neovascularization [30] . A possible explanation may be that our control group consisted of patients undergoing cataract surgery which resulted in a relatively high mean age. It is tempting to speculate that the increase in VEGF in elderly is a physiological respons to changes in the microenvironment of the eye. This hypothesis is currently under investigation. At present, it is unclear what the underlying mechanism and physiological relevance of the age-dependent increase of VEGF in the eye is. It could be argued that passive diffusion results in elevated ocular VEGF levels. This would imply a relation between serum and ocular fluid levels. However, we could not establish such a relation which makes passive diffusion of VEGF unlikely.
VEGF, also known as vascular permeability factor (VPF), was originally recognized for its ability to increase permeability of the microvasculature to circulating plasma proteins. High concentrations of VEGF were found in guinea pig and in human tumor ascites fluids [32] . Tumor ascites fluid accumulation might result from increased permeability of the blood vessels lining the peritoneal cavity due to VEGF production by tumor cells [33] . High concentrations of VEGF were measured in glioblastoma cyst fluid which is suggesting that increased vascular permeability leads to cyst formation [26] . A frequent manifestation of VHL disease is the development of cysts in various organs [1] . The 10-and 16-fold increase in VEGF concentration in two independent cysts as compared with VEGF levels in peripheral blood samples may indicate that VEGF plays a role in the formation of these cysts. The abundant expression of VEGF in renal cell carcinomas and hemangioblastomas suggest that these cells are the source of the excessive VEGF production. Although the mean VEGF concentration in serum of VHL patients was higher than in control subjects this did not reach significance. In contrast, lower levels of VEGF were found in the urine of VHL patients than in the matched control group. The role of measuring VEGF concentrations as a prognostic factor in cancer patients has yet to be determined. VEGF levels in sera from uterine, ovarian, breast and lung cancer patients were significantly higher than those in sera from individuals with no sign of cancer [34, 35] . On the other hand, in sera of patients with brain tumors no elevated VEGF levels were observed [26] . It may be argued that the observed elevated levels of VEGF reflect tumor-burden per se. In our study, however, no correlation between individual VEGF levels in serum or ocular fluid and manifestations of the disease was found. This finding suggests that in addition to VEGF other factors are required to induce the switch to the malignant phenotype.
In addition to VEGF, the concentrations of three other angiogenic factors were analysed: bFGF, IL-8 and ET-1. bFGF is one of the most potent endothelial mitogens and a chemotactic factor for endothelial cells. It is distributed widely in normal and neoplastic tissues [36] [37] [38] [39] . Basic FGF is abnormally elevated in serum and urine of patients with a wide variety of human cancers [40] . In vitro studies did not establish a regulatory effect of the VHL gene on the expression of bFGF [10] . This is supported by our observation that levels of bFGF in serum and urine of VHL patients were not different from unaffected subjects. In addition, bFGF was only expressed in the minority of VHL-related renal cell carcinoma. A limited expression of bFGF in sporadic renal cell cancer has been reported by others [41, 42] . Because in the majority of renal cell carcinomas the VHL gene is inactivated, these findings argue against an important role of bFGF in VHL disease [43] .
Because a relationship between the VHL gene and hypoxia has been suggested, IL-8 and ET-1 were included in our study [11, 12] . Both factors are angiogenic peptides and are, at least partially, regulated by hypoxia [44, 45] . Human recombinant IL-8 is angiogenic when implanted in the rat cornea and induces proliferation and chemotaxis of human umbilical vein endothelial cells [46] . Activation of endothelin receptors of brain capillary endothelial cells by ET-1 leads to mitogenesis (ET-1 being a more potent mitogen than bFGF) [47] . IL-8 and ET-1 levels in serum and urine of VHL patients were not elevated when compared to matched controls. These findings suggest that IL-8 and ET-1 can not be used as markers of disease.
In summary, the VHL tumor suppressor gene appears to regulate VEGF but not bFGF levels in vivo. Elevated levels of VEGF may play an important role in the development VHL-related vascular tumors and cysts. Measurement of angiogenic factors in serum and urine of VHL patients appears to have limited prognostic value but warrants further study. These findings may provide a framework to develop a treatment strategy which may ultimately replace surgery as the treatment of choice for VHL disease.
